Jul 27, 2020 7:00am EDT Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
Jul 20, 2020 7:00am EDT Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Jul 15, 2020 7:00am EDT Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
Jun 30, 2020 7:00am EDT Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
Jun 09, 2020 7:00am EDT Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.
Jun 08, 2020 7:25am EDT Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020
Jun 04, 2020 7:14am EDT Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer
Jun 03, 2020 7:00am EDT Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th
